| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-07-5725 |
| P698 | PubMed publication ID | 18593922 |
| P50 | author | Jesús San Miguel | Q5930658 |
| Kenneth C. Anderson | Q28421846 | ||
| Mercedes Garayoa | Q51693206 | ||
| Patricia Maiso | Q53140836 | ||
| Enrique M Ocio | Q60324819 | ||
| Atanasio Pandiella | Q83446572 | ||
| Paul G. Richardson | Q87712102 | ||
| Faustino Mollinedo | Q88826407 | ||
| Nikhil V Munshi | Q89228014 | ||
| Ciaran J McMullan | Q96049525 | ||
| Teru Hideshima | Q114455520 | ||
| Dharminder Chauhan | Q117224711 | ||
| Constantine S Mitsiades | Q117224720 | ||
| Nicholas S Mitsiades | Q117224764 | ||
| P2093 | author name string | David Vilanova | |
| Juan Carlos Montero | |||
| Gabriel Otero | |||
| Pablo Aviles | |||
| Consuelo Gajate | |||
| Glynn Faircloth | |||
| M Victoria Mateos | |||
| P2860 | cites work | Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia | Q40171821 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aplidin | Q4779975 |
| marine organism | Q124321800 | ||
| P304 | page(s) | 5216-5225 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo | |
| P478 | volume | 68 |
| Q33707607 | A multi-parameter, high-content, high-throughput screening platform to identify natural compounds that modulate insulin and Pdx1 expression |
| Q39394159 | An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs. |
| Q64889831 | Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma. |
| Q41144514 | Anticancer effects of an extract from the scallop Patinopecten yessoensis on MCF-7 human breast carcinoma cells. |
| Q64120412 | Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts |
| Q39592207 | Aplidin as a potential adjunct to radiation therapy: in vitro studies |
| Q35775249 | Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study |
| Q36733492 | BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. |
| Q36096750 | Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals |
| Q37191213 | CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin |
| Q92621278 | Characterization of Drug-like Chemical Space for Cytotoxic Marine Metabolites Using Multivariate Methods |
| Q39119280 | Combined gene expression and proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger apoptosis. |
| Q35301052 | Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis |
| Q36395803 | Current status on marine products with reversal effect on cancer multidrug resistance |
| Q33801093 | Cyclodepsipeptides from marine sponges: natural agents for drug research |
| Q37771370 | Development of target-specific treatments in multiple myeloma |
| Q50033952 | Dual Roles of Ascidian Chondromodulin-1: Promoting Cell Proliferation Whilst Suppressing the Growth of Tumor Cells |
| Q47340203 | Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. |
| Q38095958 | Experimental approaches in the treatment of multiple myeloma |
| Q39732580 | Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways |
| Q26859211 | Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) |
| Q33834080 | Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. |
| Q33980259 | Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors |
| Q34356560 | Marine antitumor drugs: status, shortfalls and strategies. |
| Q39305333 | Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model |
| Q37336468 | New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. |
| Q26822754 | Novel agents for multiple myeloma to overcome resistance in phase III clinical trials |
| Q91981315 | Oceans as a Source of Immunotherapy |
| Q35911656 | Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab |
| Q37603607 | Plitidepsin: design, development, and potential place in therapy |
| Q37816960 | Preclinical development of molecular-targeted agents for cancer |
| Q92783828 | Prognostic role of minichromosome maintenance family in multiple myeloma |
| Q35228243 | Purification and partial characterization of a new antitumor protein from Tegillarca granosa |
| Q93032749 | Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma |
| Q37891692 | Rational therapeutic options for patients with myeloproliferative neoplasms |
| Q90446915 | Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment |
| Q39587408 | Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells. |
| Q35813841 | The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo |
| Q84878923 | The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells |
| Q52646693 | Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides. |
| Q38255333 | Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back |
| Q36999167 | c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity |
Search more.